Biogen Inc. (BIT:1BIIB)

Market Cap	16.19B
Revenue (ttm)	8.51B
Net Income (ttm)	1.30B
Shares Out	n/a
EPS (ttm)	8.90
PE Ratio	12.42
Forward PE	8.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	60
Open	109.95
Previous Close	109.95
Day's Range	109.95 - 109.95
52-Week Range	101.40 - 189.25
Beta	n/a
RSI	46.61
Earnings Date	Jul 31, 2025

About Altus Power

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BIIB

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.